Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.38 |
| ▸ | CA2 | P00918 | 16/20 | 0.38 |
| ▸ | CA12 | O43570 | 14/20 | 0.38 |
| ▸ | CA9 | Q16790 | 10/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 6/20 | 0.36 |
| ▸ | CA5A | P35218 | 6/20 | 0.36 |
| ▸ | CA7 | P43166 | 6/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367404 | 0.88 | CA1 (0.38) | CA1CA2CA12CA9CA14 | |
| SCHEMBL15607880 | 0.86 | CA1 (0.38) | CA1CA2CA12CA9CA14 | |
| SCHEMBL15183379 | 0.85 | CA1 (0.39) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16367403 | 0.84 | L3MBTL1 (0.38) | — | |
| SCHEMBL16367330 | 0.82 | EGFR (0.41) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16367416 | 0.81 | LMNA (0.36) | CA1CA2CA12CA9CA14 | |
| SCHEMBL15607858 | 0.80 | CD69 (0.35) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16367358 | 0.80 | CA9 (0.40) | CA1CA2CA12CA9CA14 | |
| SCHEMBL15607943 | 0.77 | TSHR (0.47) | CA1CA2CA12CA4CA5A | |
| SCHEMBL18214993 | 0.76 | CA2 (0.48) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | CA1 289/4885CA2 215/4885CA12 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.